FDA formally pulls Oncopeptides' cancer drug after prolonged back-and-forth
More than a year after the FDA called on Oncopeptides to withdraw Pepaxto (melphalan flufenamide), the Swedish company has finally lost its appeal, and the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
